Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1701 + platinum-doublet chemotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
SHR-1701 + platinum-doublet chemotherapy is an investigational combination regimen being evaluated for the treatment of unresectable stage III non-small cell lung cancer (NSCLC). SHR-1701 is a bifunctional fusion protein (biologic) that simultaneously targets two immune-suppressive pathways: Programmed Death-Ligand 1 (PD-L1) and Transforming Growth Factor-beta Receptor II (TGF-βRII). By blocking PD-L1, it restores T-cell anti-tumor activity, while its TGF-β trap component inhibits TGF-β signaling to address immune exclusion and fibrosis in the tumor microenvironment. The platinum-doublet chemotherapy component (typically cisplatin or carboplatin paired with a second agent like pemetrexed) provides direct cytotoxic effects and may enhance tumor antigenicity. This combination is being studied as induction and consolidation therapy to improve outcomes in patients undergoing concurrent chemoradiotherapy.
- Other names
- SHR-1701 plus platinum-doublet chemotherapySHR1701 plus platinum-doublet chemotherapySHR 1701 plus platinum-doublet chemotherapySHR-1701 in combination with platinum-doublet chemotherapySHR1701 in combination with platinum-doublet chemotherapySHR 1701 in combination with platinum-doublet chemotherapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)DNATGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on SHR-1701 + platinum-doublet chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1701 + platinum-doublet chemotherapy.